Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Chemical drugs | 10 |
Herbal medicine | 6 |
Small molecule drug | 2 |
Target |
Mechanism ADRA1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date23 Jan 1990 |
Target |
Mechanism L-type calcium channel blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date17 Jan 1989 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date- |
Sponsor / Collaborator |
Start Date14 May 2018 |
Sponsor / Collaborator |
Start Date27 Jan 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Doxazosin Mesylate ( ADRA1 ) | Hypertension More | Approved |
Nilvadipine ( L-type calcium channel ) | Cardiovascular Diseases More | Clinical |
KM2013001 | Urogenital Diseases More | IND Application |
KM20140707 | Digestive System Disorders More | IND Application |
KM20140706 | Digestive System Disorders More | IND Application |